For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the arrival of Vyndamax and the formulated version represents a genuine change. These novel therapies protect the transthyretin protein, slowing its damaging build-up and reducing the severity of the disease . Individuals are now reporting benefits in their